CNS Drugs 2009;
نویسندگان
چکیده
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225 1. Efficacy in Acute Mania . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226 1.1 Critical Assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226 1.2 Major Findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227 1.3 Supportive Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228 1.4 Use in Combination: Critical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 228 2. Efficacy in the Prophylaxis of Bipolar Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 2.1 Critical Assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 2.2 Major Findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229 2.3 Data from Meta-Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 2.4 Concentration-Effect Controlled Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 2.5 Controlled Trials versus ‘Active’ Comparator . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232 2.5.1 Critical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232 2.5.2 Major Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232 2.6 Supportive Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233 2.7 Use in Combination for Maintenance Therapy: Critical Assessment. . . . . . . . . . . . . . . . . . . . . . . 233 2.8 Use in Rapid Cycling Bipolar Disorder: Critical Assessment and Major Findings. . . . . . . . . . . . . . 234 2.9 Use in Mixed States: Critical Assessment and Major Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235 2.10 Use in Bipolar II Disorder: Critical Assessment and Major Findings . . . . . . . . . . . . . . . . . . . . . . . . . 235 3. Efficacy in Acute Bipolar Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235 3.1 Use as Single Therapy: Critical Assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 235 3.2 Antidepressant Augmentation of Lithium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 4. Efficacy in Relation to Suicide and Mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 4.1 Critical Assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 4.2 Major Findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236 5. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 237 Abstract Although there has been a decrease in lithium use over several years, it isAlthough there has been a decrease in lithium use over several years, it is still recommended as a first-line mood stabilizer in all recent guidelines. It has been argued that many studies of lithium were conducted at a time when study design, assessment standards and the diagnostic criteria for patient selection were not as established as they presently are. However, recent placebo-controlled data from three-arm trials have demonstrated a definite REVIEW ARTICLE CNS Drugs 2009; 23 (3): 225-24
منابع مشابه
Ethanol Concentration and Its Correlation with CNS Suppressor Drugs in Postmortem Subjects
Background: Many studies have been done in order to interpret correctly the results of ethanol analysis and its related problems. Unfortunately, it was not easy to determine BAC rate, due to postmortem different conditions or personal and clinical differences in metabolism and excretion of ethanol. The time between death and autopsy, the environmental conditions (temperature and humidity) are i...
متن کاملMultifunctional drugs: a novel concept for psychopharmacology.
Beginning this month and appearing periodically in future columns, "Trends in Psychopharmacology" will cover a new concept and hot topic in the field, namely, that of "multifunctional drugs." The concept is presented in overview here. Future installments will cover specific drugs in greater depth. Multifunctional drugs include those agents with more than one putative therapeutic mechanism of ac...
متن کاملCNS Drugs 2009;
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 837 1. Early Stages of Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 839 2. Efficacy of Antipsychotic Drugs in First-Episode Schizophrenia . . . . . ...
متن کاملChallenges in the search for drugs to treat central nervous system disorders.
The history of drug discovery spans approximately 200,000 years. For much of this time, the identification of therapeutic agents was empirical, with the shift to a more hypothesis-driven approach occurring in the late 19th century. Since then, the objective has changed from identifying an active drug and its mechanism of action to determining therapeutic potential only after identifying drug-li...
متن کاملPharmacological fMRI and EEG for the development of novel analgesic compounds
Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) have been introduced in pharmacological studies with the aim to measure the modulation of brain activity by drugs acting directly on the central nervous system (CNS) or indirectly on its afferent input. By providing novel and specific biomarkers which could substitute or complement clinical endpoints, this approach is...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009